The present research investigated the compounds present in the low molecular mass fraction of Lentinus edodes mushroom (shiitake) extract and their anti-virulence activity against oral pathogens (reference and clinical Streptococcus mutans, Actinomyces naeslundii, and Prevotella intermedia strains). Oxalic, succinic, and quinic acids, and adenine, inosine, and uridine were identified by HPLC-DAD-ESI-MS/MS. Their anti-biofilm production and preformed biofilm disaggregation activities were studied using commercial standard compounds at different concentrations. As regards S. mutans, the highest activity was shown by adenine 5mg mL -1 both in the biofilm inhibition (BI 50%) and in the biofilm disaggregation tests (BD 20%). Considering A. naeslundi, BI values close to 80% were registered for oxalic acid at 1mg mL -1 and 2mg mL -1 and BD 50% for quinic acid 3mg mL -1 . Weaker activity was found against P. intermedia. Furthermore, different mixtures of the commercial standards were tested showing that the activity of a compound can be strongly and sometime negatively affected by the presence of the other compounds.
Introduction
Lentinus edodes is one of the largest cultivated edible mushroom in the world for its appreciable taste and flavour, and important nutritive properties.
1-4 L. edodes has a long history in oriental folklore for treatment of different health problems and thus it is considered as the elixir of life and used also for specific medical conditions.
5-6
Its use has increased over the last two decades in Western countries and a large number of investigations on its components and biological properties has been carried out. Therapeutic effects against different pathologies such as tumors 7-10 , heart diseases 1 , obesity 11 , diabetes 12 , liver ailments 13-14 , respiratory diseases 15 , inflammation [16] [17] , viral [18] [19] and bacterial infections [20] [21] , caries and gingivitis [22] [23] [24] have been confirmed or recognized.
Several bioactive components have been identified in L. edodes including both high and low molecular mass (MM) compounds possessing important pharmacological and functional properties.
Such components belong to different chemical classes, including sugars 25 , polyalchols 26 , polysaccharides [27] [28] [29] [30] , polyphenols [31] [32] , glicoproteins 33 , proteins 34 , nucleotides, nucleobases, peptides, and amino acids.
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In recent studies we identified a low MM (LMM) fraction of L. edodes possessing the ability to inhibit virulence-related properties (i.e., biofilm formation, adherence to epithelial cells, and hydroxyapatite) of oral pathogenic bacteria involved in tooth decay (Streptococcus mutans) and 7 mentioned above. After overnight growth, the bacterial culture was diluted in broth to contain 10 5 cfu mL -1 . Two-fold dilutions of test samples and fractions in 0.1 mL of BHIB were placed into wells of flat-bottomed microtiter plates. A 10 μL volume of bacterial culture was then added.
Following incubation of the plates for 18 h at 37 °C in ambient air or anaerobically, the MICs were determined. The MICs were recorded as the lowest concentration of test sample that completely inhibited visible growth of the bacteria.
Inhibition of biofilm formation by the target organisms
The capability of the selected fractions/standard compounds at different sub-MIC concentrations (see legends of Figures 2 and 3) to prevent biofilm formation was evaluated by the microtiter plate assay described by Cramton. 40 Briefly, bacterial suspensions were prepared in the appropriate growth medium containing different concentrations of the test material (pH adjusted to 7.0±0.1).
The final concentration of bacteria was either 3-5 × 10 5 cfu mL -1 (S. mutans and A. naeslundii) or 5-8 ×10 6 cfu mL -1 (P. intermedia). Aliquots (200 μL) of the cell suspensions were inoculated into the wells of 96-well polystyrene microtiter plates. The wells were preconditioned (saliva-coated) in processed whole unstimulated pooled human saliva. The collection of saliva and the preconditioning have been previously described 35, 41 (all saliva donors were given oral and written information about the purpose of the study and were asked to sign an informed consent. Tables 2 and 4 showed combined values with statistical analysis.
Disaggregation of pre-existing biofilms of the target organisms
Mature biofilms of each of the test organisms were grown into preconditioned (saliva-coated) saliva wells, on 96-well polystyrene microtiter plates as previously described. The biofilms were grown for 48 h for S. mutans (aerobic organism) and 5 days for A. naeslundii and P. intermedia (anaerobic organisms). The mature biofilms were then incubated with the test compounds overnight. To this end, aliquots of fresh medium, containing different concentrations of GFC fractions or standard compounds were added to the wells (at least in triplicate). After overnight incubation the culture medium was discarded and biofilm formation was quantified as described above (section 2.8).
Values obtained in the treated sample were compared to the controls (100%) and expressed as % biofilm disaggregation (BD). Experiments were run in triplicate and performed twice. 37 Since results obtained with reference and clinical strains were similar, Tables 2 and 5 show combined values with statistical analysis.
Statistical analyses
Data representing the mean ± SD of at least two experiments in triplicate were analyzed by the Mann-148 Whitney U test (p<0.05).
Results
In order to identify mushroom compounds able to interfere with the growth and virulence-related traits of S. mutans, A. naeslundii, and P. intermedia, the components of LMM fraction isolated from L. edodes extract were fractionated by the GFC technique (Fig. 1) . Five fractions were collected (M1-M5) according to the nominal molecular mass of their components; each fraction was submitted to sterile ultrafiltration and freeze-dried. The fractions were then tested for their antimicrobial activity (MIC assay, section 2.7) towards clinical and reference S. mutans, P.
intermedia, and A. naeslundii strains (Table 1 ). In addition, their capability to prevent biofilm formation on saliva conditioned microtiter plates and induce pre-existing biofilm disaggregation was also studied (see Material and Methods, sections 2.8 and 2.9) ( Table 2 ).
As shown in Table 1 Considering biofilm formation and disaggregation, the results obtained showed that the GFC fractions had different effects on the three bacterial species tested (Table 2 reports the average values obtained with both reference and clinical strains). All the fractions possessed very low BI activity as regards S. mutans (BI = 2-6%) while they were more active against the anaerobic bacteria (BI = 42-78%). In the case of biofilm disaggregation (BD) tests, all the fractions were able to disaggregate the biofilm preformed by cariogenic S. mutans bacteria ( BD = 22-50%) and also by gingivitis bacteria A. naeslundii (BD = 30-47%) and P. intermedia (BD = 26-74%).
As a whole, M4 fraction showed the highest activity, and therefore it was selected for further investigations to identify the active components.
By comparing their retention time, UV-Vis spectra and MS/MS fragmentation data with those of standard compounds, in the M4 fraction three organic acids, i.e. quinic, oxalic and succinic acids, (Table 3) .
Quinic, oxalic, and succinic acids were also identified in a Cichorium intybus fraction previously studied; these acids showed anti-biofilm activity, at various degree, towards S. mutans, A.
naeslundii and P. intermedia. 36 Studies performed by others have also shown that succinic acid inhibits growth of bacterial and fungal strains 42 while quinic acid derivatives are active against different bacterial strains 43, 44 , and oxalic acid is active against Bacillus cereus, Staphylococcus aureus, and Enterococcus faecalis. 45, 46 Regarding basis, it was previously found that uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa. 47 In addition, nucleosides and/or nucleotides and their analogues showed inhibitory activity towards different viruses (e.g., HIV, HBV) 48, 49 , and regulate virulence factors, biofilm formation and quorum sensing in Pseudomonas. 50 Our previous investigations showed about 25 fold higher concentration of quinic acid in an edible mushroom 51 (478 g g -1 fresh) than in C. intybus red chicory (<20 g g -1 fresh). Unpublished results from our laboratory showed that the concentration of oxalic acid in mushroom is about two fold higher than in chicory (47.5 ± 2.4 and 26.4 ± 2.8 g g -1 fresh vegetable for mushroom and chicory, respectively), while succinic acid concentration is about three fold lower than in chicory (37.2 ± 5.1 and 108.2 ± 4.7 g g -1 fresh vegetable for mushroom and chicory, respectively). Quinic and oxalic acids higher concentration in mushroom could explain the higher activity of mushroom extract, as compared to chicory extract and related LMM fraction. 36 As the results obtained for mushroom extract 35 and its fractions (Table 2) were not always consistent, thus indicating the possibility of interactions among the different components present in mushroom, it was decided to study the activity of each characterized compounds and the possibility of interactions among them, using the commercial compounds.
These standards were tested on both reference and clinical strains at increasing concentrations starting from the average values reported in literature for plant materials [52] [53] [54] [55] [56] [57] [58] (Tables 4-5 Quinic and oxalic acids, uridine, adenine, and inosine, when tested alone (Table 4) , inhibited
weakly biofilm formation by all tested S. mutans strains (BI = 21-52% at the highest concentration tested for each substance), while no activity was registered for succinic acid at any tested concentrations. In contrast, the mixtures consisting of the two commercial nucleosides, i.e. uridine 5mg mL -1 and inosine 1mg mL -1 (U5+I1), or of a nucleoside with adenine, i.e. uridine 5mg mL -1
and adenine 2mg mL -1 (U5+A2) or adenine 2mg mL -1 and inosine 1mg mL -1 (A2+I1) (Figure 2a Testing mixtures consisting of more than two standards, contrasting results were obtained ( Figure   2b ). In fact, ternary and pentenary mixtures showed in some cases higher activity values (p<0.05) than those registered for single compounds or binary mixtures (e.g., Q3+I2+A3 or Q3+O2+I2+A5+U5), while in others a decreased activity depending on the tested concentrations was observed (e.g., Q1+O2+I2+A5+U5) (Figure 2b ). This comparison points out apparent negative interactions.
Regarding reference and clinical A. naeslundii strains, very high activity was shown by oxalic acid (BI = 81-85%), quinic acid at 3.5mg mL -1 (BI = 74%), and by inosine (BI > 67%), while lower activity was presented by adenine (BI = 41-52%) and no activity was found for uridine and succinic acid (Table 4) Biofilm formation by the different P. intermedia strains was weakly inhibited by the tested mushroom compounds. In fact, the highest BI values obtained ranged from 28 to 39% for uridine and inosine alone (Table 4) ; regarding their mixtures, the highest BI values was 34% (Figure 2a ).
Any other tested mixture did not increase the inhibition of biofilm production that was lower than 26% ( Figure 2b ).
The compounds exhibited weak activity either alone or in mixtures in disaggregating biofilm formed by P. intermedia and S. mutans reference and clinical strains (Table 5) A notable activity in the disaggregation of preformed A. naeslundii biofilm was found for quinic acid at the highest concentration (Q3, BD about 50%) and inosine at all tested concentrations (BD = 37-38%); adenine at all tested concentration showed a lower activity (BD = 29-31%) ( Table 5) .
Regarding mixtures, a remarkable BD activity was observed for quinic 3.5mg mL -1 + oxalic acid 2mg mL -1 (Q3 + O2, BD = 36%) (Figure 3a) , and quinic acid 3.5mg mL -1 + inosine 2mg mL -1 + adenine 3mg mL -1 (Q3 + I2 + A3) (Figure 3b ). The other couples of basic compounds and the mixture quinic acid plus a single basic compound showed low activity values (BD = 30%) indicating negative interactions confirmed by the results given by the pentenary mixture containing the two acids and the three basic compounds that showed activity values closed to 20% (Figure 3a) .
Considering P. intermedia strains, the activity of uridine 5mg mL -1 (U5, BD = 20 -25%, depending on strain) and uridine mixed with adenine 2mg mL -1 (BD = 23 %) was weak (Table 5, Figure 3b ).
Discussion
The reported results showed that the identified compounds and all their tested mixtures are able to inhibit S. mutans biofilm production by at least 21% (with the exception of succinic acid) and A.
naeslundii by at least 32% (with the exception of uridine and succinic acid). In the case of S.
mutans, the mixtures quinic acid with inosine or uridine were able to inhibit the biofilm production more than 70% and in the case of A. naeslundii the highest detected activity was due to quinic acid plus adenine (Q3 + A2) and quinic acid plus oxalic acid (Q3 + O2), that inhibited 80% of biofilm production. Weaker activity was found for P. intermedia. In fact, only inosine, uridine and the mixture of these two standard compounds showed BI values higher than 30%.
Considering biofilm disaggregation, when biofilm was produced by S. mutans, only quinic acid in mixture with adenine or inosine gave BD values higher than 35%. Conversely, as regards A.
naeslundii, BD activity higher than 50% was found for quinic acid at the highest concentration;
adenine, inosine and the mixtures of quinic acid with oxalic acid and of adenine with inosine showed 30-40% BD capacity. Considering P. intermedia, BD activity higher than 20% was registered only for uridine. As a whole, these compounds are much more active in inhibiting biofilm formation than disaggregation. This can be explained by the fact that planktonic bacteria are more susceptible to the action of compounds present in the external environment than bacteria inside a biofilm. It is well known that cells embedded in biofilm are up to 1000-fold more resistant to antibiotics compared to their free living counterpart. 59 However, the fact that our results pointed out that the disaggregation action occurs with the inhibition of biofilm production by A. naeslundii and S. mutans could be important in reinforcing capability of these compounds in their potential use as anti-caries and anti-gingivitis agents.
Another important point of this study is the demonstration that the outcome of exposure of bacteria to mixtures is either a summation effect of each compound present in the mixture (although a complete inhibition of biofilm formation was never observed) or an antagonistic effect. The outcome seems to be dose dependent. In general, low doses of the compounds in combination produce additive effects, whereas higher doses produce antagonistic effects probably as a result of chemical-physical negative interactions among the different compounds.
When evaluating the relevance of the obtained results, we must also consider that bacteria were exposed to the tested compounds (alone or in combination) up to 5 days. Therefore, the possibility that the compounds are transformed and modified in their biological activity by growing bacteria should be taken into account. Although elucidation of the molecular mechanisms of the bioactivity of the identified compounds is beyond the scope of this study, it can be hypothesized that they might either inhibit the activity of key enzymes involved in matrix formation or hamper quorum sensing system. It is also possible that the tested components interfere with adhesion/co-aggregation mechanisms by binding outer membrane proteins of Gram-negative bacteria and disorganizing the phospholipid bilayer. 60 In Gram-positive cells, particularly as regards acid components, it is possible that the active components modify the electrical charge of the cell wall thus altering the electrical potential and/or the hydrophobicity of the surface. This is supported by previous observations showing that exposure to phenolic acids reduces the negative charge of the bacterial surface. 61 These options are currently under investigation in our laboratory.
Conclusion
The evolution, selection and spread of bacterial resistance to a wide range of antibiotics makes the development of novel strategies to prevent and treat bacterial infections crucial. An increasing interest in identifying anti-infectious components that exist in dietary sources has been registered since the 1980s.
In this context, the data reported here show that L. aedodes, a mushroom to which many beneficial effects on human health have been attributed, contains a number of LMM compounds potentially useful for combating some of the bacteria responsible for certain oral cavity diseases, as they were active in vitro against some of the virulence-related traits of S. mutans, the main etiological agent of dental caries in humans, and A. naeslundii and P.intermedia, both of which are involved in gingivitis.
However the results obtained are based on in vitro studies only, caution is therefore advised in the interpretation of the in vivo significance of our findings. Further investigations are needed to test the safety and efficacy of L. aedodes LMM compounds in vivo and to define the actual impact on oral health of the consumption of Lentinus mushrooms consumption in the diet.
Overall, these studies contribute to both the design of new antibacterial strategies and to reverse the common perception of the negative effects of dietary constituents on the oral microbiota and oral health, in that foods/food components are not necessarily deleterious (e.g. sucrose and dental caries) but could possibly exert a beneficial effect.
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